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Summary 
Glycosylation is an abundant co- and post-translational protein modification of importance to 
protein processing and activity. While not template-defined, glycosylation does reflect the biological 
state of an organism and is a high-potential biomarker for disease and patient stratification. 
However, to interpret a complex but informative sample like the total plasma N-glycome (TPNG), it is 
important to establish its baseline association with plasma protein levels and systemic processes. 
Thus far, large scale studies (n > 200) of the TPNG have been performed with methods of 
chromatographic and electrophoretic separation, which, while being informative, are limited in 
resolving the structural complexity of plasma N-glycans. Mass spectrometry (MS) has the 
opportunity to contribute additional information on, among others, antennarity, sialylation, and the 
identity of high-mannose type species. 
Here, we have used matrix-assisted laser desorption/ionization (MALDI)-Fourier transform ion 
cyclotron resonance (FTICR)- MS to study the TPNGs of 2,144 healthy middle-aged individuals from 
the Leiden Longevity Study, to allow association analysis with markers of metabolic health and 
inflammation. To achieve this, N-glycans were enzymatically released from their protein backbones, 
labeled at the reducing end with 2-aminobenzoic acid, and following purification analyzed by 
negative ion mode intermediate pressure MALDI-FTICR-MS. In doing so, we achieved the relative 
quantification of 61 glycan compositions, ranging from Hex4HexNAc2 to Hex7HexNAc6dHex1Neu5Ac4, 
as well as that of 39 glycosylation traits derived thereof. 
Next to confirming known associations of glycosylation with age and sex by MALDI-FTICR-MS, we 
report novel associations with C-reactive protein (CRP), interleukin 6 (IL-6), body mass index (BMI), 
leptin, adiponectin, HDL cholesterol, triglycerides (TG), insulin, gamma-glutamyl transferase (GGT), 
alanine aminotransferase (ALT) and smoking. Overall, the bisection, galactosylation and sialylation of 
diantennary species, the sialylation of tetraantennary species, and the size of high-mannose species 
proved to be important plasma characteristics associated with inflammation and metabolic health. 
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Introduction 
Glycosylation is a ubiquitous co- and post-translational protein modification of functional relevance 
to the processing and activity of the conjugate. Examples include quality control during protein 
folding, regulation of circulatory half-life, and modulation of receptor interactions by either providing 
the recognition motif or by affecting protein conformation (1-7). Consequentially, glycosylation has 
been associated with a multitude of diseases and states thereof, among which the progression and 
metastasis of cancer and the remission of rheumatoid arthritis (8-11). Because the process of 
glycosylation is not template-defined, glycosylation integrates a large series of cellular conditions 
such as glycosidase/glycosyltransferase abundance and activity, endoplasmic reticulum (ER)/Golgi 
localization and nucleotide sugar availability, and reflects the intricate biological state of an organism 
(1, 2, 12). To establish glycosylation as biomarker for (early detection of) disease and patient 
stratification, analysis of an easily obtainable biofluid such as plasma is of great interest (13, 14). 
Observed effects in a total plasma N-glycome (TPNG), i.e. the released N-glycans from all plasma 
proteins, are highly informative but difficult to comprehend due to the complex contributions from 
relative protein glycoforms and overall glycoprotein abundances (15, 16). 
To interpret the TPNG in a context of human health and disease it is of importance to establish the 
behavior of N-glycans, and groups of N-glycans, in relation to plasma protein levels and systemic 
processes such as inflammation and metabolism. Previous studies of suitable size (n > 200) have 
performed this to various degrees, finding plasma N-glycans to be highly associated with e.g. age, 
sex, inflammation, body mass index (BMI), cholesterol and lipid levels (17-24). However, these 
studies have either been performed on single proteins, immunoglobulin G (IgG) being a particularly 
well-studied example, or predominantly by methods of liquid chromatographic and electrophoretic 
separation (e.g. (ultra)-high-performance liquid chromatography (U)HPLC and capillary gel 
electrophoresis with laser-induced fluorescence detection (CGE-LIF)). While of high analytical value - 
the techniques can separate analytes that are the same in monosaccharide composition (e.g. 
Hex4HexNAc4dHex1) but differ in glycan structure (e.g. ɲ1,3-branch galactosylation versus ɲ1,6-
branch galactosylation) - the complexity of the TPNG means that observed signals generally comprise 
a variety of distinct compositions (25-28). Mass spectrometry provides orthogonal information from 
these methodologies, as it does not distinguish isomers but instead unambiguously evaluates glycans 
on a compositional level (29-31). To date, a large mass spectrometric TPNG study remains to be 
performed for revealing associations with markers of inflammation and metabolic health (32-34). 
Here, we have used high-resolution intermediate-pressure matrix-assisted laser 
desorption/ionization (MALDI)-Fourier transform ion cyclotron resonance (FTICR)-mass spectrometry 
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(MS) to profile the total plasma N-glycosylation of 2,144 middle-aged individuals of the Leiden 
Longevity Study (LLS) (35). While MALDI-MS is reported to lead to underestimation of sialylated 
glycan species due to in-source and metastable decay, a phenomenon particularly visible with 
reflectron-based MALDI-time-of-flight (TOF)-MS, the intermediate pressure of the here-presented 
method prevents the residue loss and allows for the repeatable analysis of species carrying up to 
four sialic acids (36-41). The 61 plasma N-glycan compositions we detected by the method, as well as 
39 glycosylation traits mathematically derived thereof, showed to highly associate with not only age 
and sex, but also with clinical markers of inflammation, liver function, cholesterol, insulin, and lipid 
metabolism. 
Experimental Procedures 
Participants 
The LLS, described in detail previously (35, 42), is a family-based study comprising 1,671 offspring of 
421 nonagenarians sibling pairs of Dutch descent, and the 744 partners of these offspring. A total of 
2,144 individuals with clinical blood parameters available were included in the current analysis. The 
study protocol was approved by the Leiden University Medical Center ethical committee and an 
informed consent was signed by all participants prior to participation in the study. 
All standard blood measurements were performed in non-fasting venous blood samples using fully 
automated equipment. Glucose, high-sensitivity C-reactive protein (hsCRP), triglyceride (TG), total 
cholesterol and high-density lipoprotein cholesterol (HDL) levels were measured on the Hitachi 
Modular P800 (Roche Diagnostics, Mannheim, Germany). Free triiodothyronine (T3) levels were 
measured on the Modular E170 (Roche Diagnostics). Low-density lipoprotein cholesterol (LDL) levels 
were calculated using the Friedewald formula (43), and set to missing if plasma TG levels exceeded 
4.52 mmol/L. Insulin levels were measured on the Immulite 2500 (DPC, Los Angeles, CA). Specific 
sandwich enzyme-linked immunosorbent assays (ELISA) were used for the determination of 
adiponectin (R&D Systems Europe, Abingdon, UK), leptin (Diagnostics Biochem Canada, Dorchester, 
Canada) and interleukin 6 (IL-6) levels (Sanquin Reagents, Amsterdam, The Netherlands). Alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST) levels were measured using the NADH 
(with P- ?഻-P) methodology (Modular P800, Roche Diagnostics), and gamma-glutamyl transferase 
(GGT) levels using the L-gamma-glutamyl-3-carboxy-4-nitroanilide substrate methodology (Modular 
P800, Roche Diagnostics). Dehydroepiandrosterone sulfate (DHEA-S) levels were measured with an 
Architect delayed one-step immunoassay (Abbot, Wiesbaden, Germany). Hypertension was defined 
as having a systolic blood pressure > 140 and a diastolic blood pressure > 90. Antihypertensive 
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medication included diuretics, beta-blockers, calcium channel blockers, and agents acting on the 
renin-angiotensin system. Cytomegalovirus (CMV) serostatus was determined by ELISA using the 
CMV-IgG ELISA PKS assay (Medac, Wedel, Germany). 
N-glycan preparation 
N-glycans from total plasma proteins from participants of the LLS were released, labeled with 2-
aminobenzoic acid (2-AA) (Sigma-Aldrich, Steinheim, Germany) to allow negative mode mass 
spectrometric detection, and purified using hydrophilic-interaction liquid chromatography (HILIC)-
solid-phase extraction (SPE) as previously described (44). Specifically, 20 ʅ> of 2% sodium dodecyl 
sulfate (SDS) (US BioChem, Cleveland, OH) was added to 10 ʅ> plasma, randomly distributed across 
27 96-well plates, followed by protein denaturation for 10 min at 60 °C and subsequent 
neutralization of the SDS by 10 ʅL 4% Nonidet P-40 substitute (NP-40) (Sigma-Aldrich). Then, after 
addition of 0.5 mU peptide-N-glycosidase F (PNGase F; Roche Diagnostics) in 10 ʅL 5x phosphate 
buffered saline solution, the N-glycans were released overnight at 37 °C. Without intermediate 
purification, the N-glycans were labeled for 2 h at 65 °C with the addition of 50 ʅL 48 mg/mL 2-AA 63 
mg/mL NaCNBH3 (Merck, Darmstadt, Germany) in a 10:3 (v/v) mixture of dimethylsulfoxide (DMSO; 
Sigma-Aldrich) and glacial acetic acid (Merck). HILIC-SPE was subsequently performed using 40 mg 
microcrystalline cellulose (Merck) in 96-ǁĞůů ? ? ? ?ʅŵ',W-filter plates (Pall, Ann Arbor, MI). All wells 
of the filter plate were washed using water and subsequently equilibrated using 80:20 (v/v) 
acetonitrile (ACN; Biosolve, Valkenswaard, The Netherlands):water. The labeled N-glycan samples 
were then applied to the wells in 80% ACN, and the wells were washed using ACN:water (80:20 v/v). 
Purified 2-AA labeled N-glycans were eluted in 0.8 mL deep well collection plates (ABgene via 
Westburg, Leusden, The Netherlands) using 400 ʅ> water. 
Carbon-SPE 
Prior to analysis by MALDI-FTICR-MS, samples were additionally desalted using carbon SPE. To 
achieve this, 100 ʅ> of graphitic porous carbon (Grace, Deerfield, IL) was applied to each well of an 
OF1100 96-well polypropylene filter plate with a 10 µm polyethylene frit (Orochem Technologies, 
Lombard, IL) using a 96-well column loader (Millipore, Billerica, MA). The stationary phase was 
activated and conditioned with 2 x 200 µL ACN:water (80:20 v/v) and 3x 100 µL 0.1% trifluoroacetic 
acid (TFA; Sigma-Aldrich) in water, respectively. Of the 2-AA labeled N-glycans, 100 ʅ>were loaded 
into the wells and washed using 3x 100 µL 0.1% TFA in water. Slight vacuum was applied to facilitate 
the procedure. The 2-AA labeled N-glycans were eluted into a V-bottom microtiter plate (Nunc, 
Roskilde, Denmark) using 3 x 30 ʅ> of freshly prepared ACN:water (80:20 v/v) containing 0.1% TFA by 
centrifugation at 500 rpm (154 mm rotational diameter). 
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MALDI-FTICR-MS analysis 
One ʅ> of 2-AA labeled N-glycans was spotted in quadruplicate on a 384-AnchorChip target plate 
(Bruker Daltonics, Bremen, Germany) and air-dried. Subsequently, 1 PL of 2,5-dihydroxybenzoic acid 
(2,5-DHB; Bruker Daltonics) matrix (20 mg/mL in ACN:water; 50:50 (v/v)) was applied to the spots 
and left to dry. To generate microcrystals, 2 x 1 ʅ> of ethanol was applied to the spots for 
recrystallization prior to mass spectrometric analysis. 
The 9.4 T FTICR APEX-ultra mass spectrometer was equipped with a dual electrospray ionization 
(ESI)/MALDI ion source (Apollo II) incorporating a quadrupole mass filter and a smartbeam laser 
system. Before analysis, the instrument was externally calibrated by peptide calibration standard 
(Bruker Daltonics). All experiments used a laser spot size of approximately 150 ʅm, laser fluence 
slightly above threshold, and a laser repetition rate of 200 Hz. To allow the semi-quantitative analysis 
for the range of expected N-glycans, all samples were analyzed using two methods: one optimized 
for lower m/z ions (approximately m/z 1,000 to 2,500) and another optimized for higher m/z ions 
(approximately m/z 2,200 to 4,000). The quadrupole was operated in rf-only mode with the selection 
masses set to m/z 1,650 and 2,500 for low-mass and high-mass measurements respectively. A 
customized experiment sequence (pulse program) was used, in which the multiple ICR-fill parameter 
was reconfigured to approximate a random-walk functionality (38). Briefly, the ions produced from 
50 laser shots were accumulated in a hexapole and then transferred through the rf-only quadrupole 
to the collision cell. The sample stage was then moved 200 ʅm, and fresh sample interrogated with 
the next 50 laser shots. This cycle was performed nine times, effectively accumulating ions from 450 
laser shots in the collision cell. The accumulated ions were then transferred to the ICR cell for a mass 
analysis scan. Each spectrum is the sum of eight such scans. All data were acquired using 
ApexControl 3.0.0 software (Bruker Daltonics) in expert mode, controlled by Hystar 3.8 software 
(Bruker Daltonics) for automatic measurement. In total, 20,736 spectra were recorded, these being 
for each biological sample a quadruplicate of low- as well as high-mass measurements. 
Data processing 
Following acquisition, representative low- and high-mass spectra were internally calibrated in 
DataAnalysis 4.2 (Bruker Daltonics) using a set of expected glycan masses (Table S1). Using the 
calibrated spectra, 37 glycan compositions were manually assigned within the low mass 
measurements (H4N2 to H5N4S1), and 25 within the high mass measurements (H5N4S1 to 
H7N6F1S4), using mass and parts-per-million (ppm) errors to validate the assignments (Table S1) (H 
= hexose; N = N-acetylhexosamine; F = deoxyhexose (fucose); S = N-acetylneuraminic acid). In 
addition, peak widths were assessed per composition to allow precise area integration (Table S1). 
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The resulting 61 compositions (H5N4S1 being present in both the low- and high-mass spectra) were 
in agreement with previously reported observations, as well as knowledge of the biological synthesis 
of N-glycans (2, 27, 45, 46). 
To achieve repeated extraction of the list of glycan compositions from the 20,736 MALDI-FTICR-MS 
measurements (10,368 low-mass and 10,368 high-mass), the spectra were converted to simple text 
based format (x,y) using msconvert from ProteoWizard 3.0.5622 (47). The raw mass spectrometric 
data has been made publicly available in the MassIVE repository (massive.ucsd.edu) titled MALDI-
FTICR-MS total plasma N-glycomics with ID: MSV000080307. Spectrum calibration, analyte 
integration and spectrum curation was performed using MassyTools 0.1.5.0 (48). In short, spectra 
were calibrated by applying the least variance second degree polynomial fit through a set of 
calibration masses (Table S1). During this step, spectra were excluded from further analysis when 
not all calibrants were detected with intensities at least three-fold higher than the maximum signal 
deviation within the local noise (MinMax; roughly corresponding to a root-mean-square (RMS) 
signal-to-noise ratio (S/N) of 9). This led to the exclusion of 470 low-mass and 372 high-mass spectra. 
Glycan compositions from the analyte list were subsequently integrated by summing and grouping 
the areas of 95% of the theoretical isotopic envelope belonging to that composition. Prior to 
summation, each isotope was integrated using the peak widths previously established, and an equal 
width local background (within a window of 50 Thomson) was subtracted from these. To further 
ensure data quality, spectra were removed if more than 5% of the total analyte area was below S/N 
3 (MinMax), which led to the additional exclusion of 305 low-mass and 424 high-mass spectra. After 
additional curation of clinical samples with no available information on age and sex, we retained a 
total of 16,346 spectra (8,194 low-mass and 8,152 high-mass), yielding glycosylation information on 
2,144 individuals. 
To arrive at one set of glycan values per individual, the replicate spectra for the low- and high-mass 
spectra were averaged for that individual. In case of low-mass spectra, 1,878 averages were 
constructed from 4 spectra, 170 from 3, 76 from 2 and 20 from 1 (Figure S1). For the high-mass 
spectra, 1,857 averages were constructed from 4 spectra, 177 from 3, 83 from 2 and 27 from 1. To 
reconstruct the overview of the total plasma N-glycome, the low- and high-mass averages were 
normalized on the value of their overlapping composition H5N4S1, and subsequently combined. The 
resulting combined pattern was normalized by dividing each glycan value by the sum of all glycan 
values (total area normalization). Hereof, we calculated derived glycosylation traits on basis of 
enzymatic steps and protein groupings (Table S2). Glycan and derived trait variation within the 
replicate low-mass and high-mass measurements was assessed on the basis of mean, standard 
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deviation (SD) and coefficient of variation (CV) (Figure S2; Figure S3). Mass spectrometric figures 
were exported from DataAnalysis 4.2 (Bruker Daltonics) and annotated with glycan depictions 
following the symbol nomenclature proposed by the Consortium for Functional Glycomics (CFG), 
created in GlycoWorkbench 2.1 build 146 (49, 50). 
Data analysis 
Throughout data analysis we employed R 3.1.2 in an environment of RStudio 0.98.1091 (RStudio 
Team, Boston, MA) (51). In case of significance testing, a study-wide significance threshold was 
maintained of ɲ = 1.00·10-5, values below or equal being considered statistically significant. The value 
arises from being the lower bound of the order of magnitude of an ɲ = 0.05 significance threshold 
Bonferroni corrected for the total number of regression tests throughout the study (number of tests 
= 27 phenotypes · 100 glycan features + 26 sex comparisons + 25 age comparisons = 2,751; ɲ = 0.05 / 
2,751 = 1.82·10
-5
 у ? ? ? ? ? ? ?-5). 
To limit the experimental component within the sample variability, batch correction was performed 
on the glycan and derived trait variables using the R package ComBat, using sample plate as batch 
(52). To limit outlier influence, individual glycosylation values exceeding a 5 times SD value from the 
mean of that variable were excluded from statistical analysis. Insulin, hsCRP, IL-6, TG, adiponectin, 
leptin, ALT, AST, GGT, and DHEA-S levels were transformed to the natural logarithm due to non-
normal distribution of the data. In addition, to obtain interpretable estimates, the glycosylation 
variables were scaled before analysis (i.e., mean subtraction and division by SD). 
Association of variables with age and sex 
Linear and logistic regression analyses were performed to establish the association between age and 
sex (female = 0; male = 1) as outcome variables, and non-glycan clinical variables (Table 1), glycans 
(Table 2) and derived glycosylation traits (Table 3) as predictor variables. As no glycosylation 
differences were found between LLS offspring and partners (a grouping to test predisposition for 
longevity), these individuals were grouped for all analyses. Furthermore, since the LLS contains 
multiple offspring from the same family, within-family (between-siblings) dependence was taken into 
account by using a sandwich estimator for the standard errors (53). 
Association of glycosylation with clinical variables 
To eliminate possible confounding effects, age, sex and the interaction thereof were included as 
covariates in further models. For these analyses, the remaining non-glycan variables were used as 
outcome (using linear and logistic regression for respectively continuous and dichotomous variables), 
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while glycans and derived traits were used as predictor (model: non-glycan ~ ɴ1·age + ɴ2·sex + 
ɴ3·age*sex + ɴ4·glycan). 
To visualize the association between non-glycans and (derived) glycan traits, the t-statistics (or Wald 
statistics in case of logistic regression, both ɴ4 / SE4) from the models were expressed in heatmap 
format. Sorting of the heatmap variables was performed using hierarchical clustering (Euclidean 
distance, complete linkage). 
Results 
To investigate the association of plasma protein N-glycosylation with clinical markers of metabolic 
health and inflammation, we analyzed the total plasma N-glycomes of 2,144 middle-aged individuals 
of the LLS. N-glycans were enzymatically released from their protein backbones, labeled at the 
reducing end with 2-AA, purified by HILIC- and carbon-SPE, and analyzed by intermediate pressure 
MALDI-FTICR-MS. The acidic tag 2-AA allowed the joint negative mode mass spectrometric detection 
and relative quantification of neutral and sialylated glycan species, whereas the intermediate 
pressure of the measurement limited the decay commonly observed for sialylated glycans with 
MALDI (Figure 1) (36-41). 
Measurement variability 
Following spectrum curation, we retained a total of 16,346 mass spectra originating from low- and 
high-mass measurements of MALDI spotting quadruplicates for each individual. In the measurement 
optimized for lower masses (m/z 1,000 to 2,500) 37 N-glycans could be detected, ranging from H4N2 
to H5N4S1, with an average absolute ppm error of 2.24 (SD ± 3.18). In the measurement optimized 
for higher masses (m/z 2,200 to 4,000) 25 additional N-glycans were detected, from the overlapping 
composition H5N4S1 to H7N6F1S4, the average absolute ppm error being 3.65 (SD ± 3.98) (Table S1). 
Based on literature, the glycan compositions within the TPNG were presumed to have certain 
structural features (16, 27, 45, 46). Examples of this are the antennarity, judged as the number of N-
acetylhexosamines minus two unless bisected, and bisection, judged to be the case if the number of 
N-acetylhexosamines equaled five and the number of hexoses five or less. While these structural 
assignments are expected to represent the majority of structures contributing to an MS signal, 
additional structural isomers are likely to be present in the signals. For example, a composition 
assigned as tetraantennary may instead contain diantennary structures with two N-
acetyllactosamine repeats, and the bisected species could be triantennary with incomplete 
galactosylation.  
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Assessing repeatability, an example quadruplicate measurement from a single individual yielded an 
average CV of 6.52% (SD ± 3.42%) for the 10 most abundant signals in the low-mass measurement 
(total area normalized for the mass range), and an average CV of 5.97% (SD ± 2.53%) for the 10 most 
abundant signals in the high-mass measurement (Figure S2A; Figure S2B). Combining the 
measurements by the overlapping composition H5N4S1 yielded for the 20 must abundant species an 
average CV of 9.29% (SD ± 5.88%) (Figure S2C). Derived glycosylation traits, constructed to provide 
mathematical expressions of monosaccharide differences and groupings with structural similarity, 
showed a lower CV, a phenomenon previously observed for mass spectrometric plasma glycomics 
(54), i.e. on average 1.20% (SD ± 0.84%) for the 20 most abundant members (Figure S2D). For a 
listing of derived traits and their calculations see Table S2.  
In total, the glycosylation analysis workflow allowed for 2,144 individuals the relative quantification 
of 61 N-glycan compositions and 39 derived traits. The LLS provided an additional 27 clinical variables 
to facilitate association analysis. Next to age and sex, measures were included on liver function (GGT, 
ALT, AST, AST/ALT), glucose metabolism (glucose, insulin, glucose/insulin), lipid metabolism 
(cholesterol, LDL-C, HDL-C, cholesterol/HDL-C, TG, lipid lowering medication, leptin, adiponectin), 
inflammation (hsCRP, IL-6), blood pressure (hypertension, antihypertensive medication), adrenal 
function (DHEA-S), thyroid function (free T3), as well as information on BMI, smoking and CMV 
infection, and familial propensity for longevity (Table 1). 
Association of glycosylation with age and sex 
Glycosylation was found to highly associate with age and sex by respectively linear and logistic 
regression analysis (Figure 2; Table 2; Table 3). A GEE approach was used for all statistical analysis to 
adjust the standard errors (SE) for between-sibling dependence, and a study-wide significance 
threshold was maintained of ɲ = 1.0·10-5. Changes with aging included a decrease of galactosylation 
of diantennary glycans, visible most specifically for the galactosylation of nonsialylated diantennaries 
with fucose (ɴA2FS0G = -2.82 SE ± 0.13; pA2FS0G < 2.2·10-16) and without fucose (ɴA2F0S0G = -1.34 ± 0.15; 
pA2F0S0G < 2.2·10
-16
). These changes were mainly driven by the increases in glycan compositions H3N4 
(ɴH3N4 = 1.21 ± 0.14; pH3N4 < 2.2·10-16), H3N5 (ɴH3N5 = 1.68 ± 0.14; pH3N5 < 2.2·10-16), H3N4F1 (ɴH3N4F1 = 
1.50 ± 0.14; pH3N4F1 < 2.2·10
-16
), H3N5F1 (ɴH3N5F1 = 1.67 ± 0.14; pH3N5F1 < 2.2·10-16) and the decreases in 
H5N4F1 (ɴH5N4F1 = -1.60 ± 0.15; pH5N4F1 < 2.2·10-16) and H5N4F1S1 (ɴH5N4F1S1 = -0.81 ± 0.15; pH5N4F1S1 = 
4.5·10
-8
). Further increasing with age were the bisection of nonsialylated fucosylated diantennaries 
(ɴA2FS0B = 0.77 ± 0.14; pA2FS0B = 6.7·10-8), sialylation per galactose of fucosylated diantennaries (ɴA2FGS = 
1.14 ± 0.15; pA2FGS = 9.8·10
-15
), and the fucosylation of both tri- and tetraantennary compositions (ɴA3F 
= 0.82 ± 0.15; pA3F = 7.4·10
-8
 and ɴA4F = 0.77 ± 0.15; pA4F = 2.0·10-7). 
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Fucosylation of triantennary and tetraantennary structures (A3F and A4F) proved also to be a major 
glycosylation difference between females and males (female = 0; male = 1) (ɴA3F = 0.73 ± 0.05; pA3F < 
2.2·10
-16
 and ɴA4F = 0.74 ± 0.05; pA4F < 2.2·10-16), driven by higher male values in all fucosylated tri- 
and tetraantennary compositions, such as H6N5F1S3 (ɴH6N5F1S3 = 0.61 ± 0.05; pH6N5F1S3 < 2.2·10-16) and 
H7N6F1S4 (ɴH7N6F1S4 = 0.45 ± 0.05; pH7N6F1S4 < 2.2·10-16), and significantly lower levels of all 
nonfucosylated tri- and tetraantennary compositions, such as H6N5S3 (ɴH6N5S3 = -0.61 ± 0.05; pH6N5S3 < 
2.2·10
-16
) and H7N6S4 (ɴH7N6S4 = -0.26 ± 0.05; pH7N6S4 = 5.8·10-8). Furthermore, males proved to have 
lower bisection of diantennary fucosylated species (ɴA2FB = -0.27 ± 0.04; p = 3.8·10-10) when 
compared to females, but did have a higher sialylation per galactose of tetraantennary 
nonfucosylated compositions (ɴA4F0GS = 0.34 ± 0.04; p = 2.5·10-14). 
Association glycosylation with inflammation and metabolic health 
Regression analysis was used to establish the relationship between the glycosylation traits and 
clinical markers, adding age, sex and the interaction thereof as covariates to limit their confounding 
influence (Table S3). The t-statistics (or Wald-statistics; both ɴ4 / SE4) arising from the models were 
expressed in clustered heatmap format (Figure 3; for a heatmap visualization of the results without 
age and sex adjustment see Figure S4). Significantly associating with a selection of derived 
glycosylation traits were hsCRP (23 statistically significant associations out of a possible 39), GGT 
(14), BMI (13), leptin (13), smoking (10), TG (9), insulin (7), the ratio of total cholesterol and HDL (7), 
the ratio of glucose and insulin (5), adiponectin (5), HDL (4), IL-6 (3), ALT (2), the ratio of ASL and ALT 
(1) and lipid medication (1) (Table S4; Table S5). Only individual N-glycan associations could be 
proven for AST, glucose, cholesterol, LDL and free T3, whereas no associations were found for 
hypertension, the usage of antihypertensive medication, DHEA-S and CMV infection. 
Inflammatory marker hsCRP showed the most associations with the total plasma N-glycome, 
including a positive association with tri- and tetraantennary glycans (ɴA3 = 0.24 ± 0.03; pA3 < 2.2·10-16 
and ɴA4 = 0.20 ± 0.03; pA4 = 2.9·10-13) at the expense of high-mannose (ɴM = -0.18 ± 0.02; pM = 1.2·10-
13
), hybrid (ɴHy = -0.24 ± 0.03; pHy < 2.2·10-16), monoantennary (ɴA1 = -0.17 ± 0.02; pA1 = 1.8·10-12) and 
diantennary species (ɴA2 = -0.25 ± 0.03; pA2 < 2.2·10-16). While fucosylation of diantennary species 
proved to decrease with higher hsCRP levels (ɴA2F = -0.13 ± 0.02; pA2F = 1.5·10-7), an increase was seen 
in the fucosylation of triantennary species (ɴA3F = 0.13 ± 0.03; pA3F = 1.0·10-6). Additional increases 
were found for sialylation of (most specifically) fucosylated diantennary (ɴA2FGS = 0.25 ± 0.02; pA2FGS < 
2.2·10
-16
) and triantennary (ɴA3FGS = 0.15 ± 0.02; pA3FGS = 1.0·10-9) species, as well as an increase in 
average high-mannose size (ɴMM = 0.13 ± 0.02; pMM = 7.9·10-8) and a decrease in bisection of the 
nonfucosylated diantennaries in particular (ɴA2F0B = -0.14 ± 0.02; pA2F0B = 1.4·10-8). Notably, while 
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galactosylation of nonsialylated diantennaries without fucose increased (ɴA2F0S0G = 0.12 ± 0.02; 
pA2F0S0G = 2.6·10
-7
), galactosylation of the same species, but with fucose, decreased instead (ɴA2FS0G = -
0.20 ± 0.03; pA2FS0G = 1.7·10
-12
). Interestingly, the associations observed with hsCRP could only in part 
be translated to the upstream cytokine IL-6 (55, 56), which only showed reproduction of the 
decreased A2F galactosylation (ɴA2FS0G = -0.19 ± 0.03; pA2FS0G = 4.6·10-12) and increased sialylation per 
galactose thereof (ɴA2FGS = 0.25 ± 0.02; pA2FGS < 2.2·10-16). 
BMI and leptin proved highly similar with respect to total plasma N-glycosylation associations, and 
showed considerable overlap with the aforementioned hsCRP as well. Taking an increase in BMI as 
example, galactosylation was decreased for fucosylated diantennary species (ɴA2FS0G = -0.55 ± 0.10; 
pA2FS0G = 9.6·10
-9
) and increased for nonfucosylated variants (ɴA2F0G = 0.58 ± 0.09; pA2F0G = 9.9·10-12). 
Changes were also seen with average high-mannose size (ɴMM = 0.89 ± 0.08; pMM < 2.2·10-16), 
bisection of nonfucosylated diantennary species (ɴA2F0B = -0.39 ± 0.08; pA2F0B = 2.0·10-6), and 
sialylation of diantennary glycans (ɴA2GS = 0.60 ± 0.08; pA2GS = 3.1·10-13). All of these effects were 
replicable within both leptin and hsCRP. However, shared with leptin but not seen with hsCRP, was 
the negative association of BMI with the sialylation of tetraantennary species, and specifically the 
nonfucosylated variants thereof (ɴA4F0GS = -0.74 ± 0.08; pA4F0GS < 2.2·10-16). When including hsCRP and 
leptin as variables in the model between BMI and glycosylation, most associations between the 
latter two are lost with the exception of high-mannose size (ɴMM = 0.32 ± 0.07; pMM = 4.0·10-7) and a 
strong remaining trend with glycan composition H4N4S1 (ɴH4N4S1 = -0.24 ± 0.07; pH4N4S1 = 1.8·10-4) 
(Table S6). 
The liver marker GGT showed major associations with the total plasma N-glycome, while AST, ALT 
and the ratio thereof were of only minor influence. GGT appeared similar to hsCRP in changes of 
increased galactosylation of nonfucosylated diantennary glycans (e.g. ɴA2F0G = 0.08 ± 0.02; pA2F0G = 
2.5·10
-7
), sialylation of fucosylated diantennaries (e.g. ɴA2FGS = 0.09 ± 0.01; pA2FGS = 9.9·10-12), as well 
as an overall increased in antennarity (e.g. ɴA3 = 0.07 ± 0.01; pA3 = 3.7·10-8). However, the marker 
showed a decrease in tetraantennary sialylation similar to BMI and not hsCRP (ɴA4F0GS = -0.11 ± 0.01; 
pA4F0GS < 2.2·10
-16
), while lacking the decreasing galactosylation of nonsialylated fucosylated 
diantennaries (A2FS0G) prominently seen in both BMI and hsCRP. 
Clinical markers considered of beneficial metabolic nature, in our study represented by 
glucose/insulin, HDL-C and adiponectin (57, 58), showed associations largely opposite to those 
established for hsCRP, BMI and GGT. Examples of this include, in case of adiponectin, the decreased 
galactosylation of nonfucosylated diantennaries (ɴA2F0G = -0.06 ± 0.01; pA2F0G = 3.1·10-8), a decreased 
sialylation of diantennaries (ɴA2GS = -0.05 ± 0.01; pA2GS = 2.1·10-6), a decreased average high-mannose 
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size (ɴMM = -0.08 ± 0.01; pMM = 1.7·10-15) and an increased sialylation of tetraantennary 
nonfucosylated species (ɴA4F0GS = 0.06 ± 0.01; pA4F0GS = 3.1·10-9). 
Interestingly, the only clinical markers affecting tri- and tetraantennary fucosylation (after correction 
for sex) proved to be smoking with a positive association (ɴA3F = 0.50 ± 0.08; pA3F = 2.6·10-10 and ɴA4F = 
0.46 ± 0.08; p = 2.3·10
-8
), and TG levels with a negative association (ɴA3F = -0.09 ± 0.01; pA3F = 8.4·10-14 
and ɴA4F = -0.09 ± 0.01; pA4F = 1.6·10-13). In addition, smoking was also the only clinical variable to 
positively associate with the bisection of fucosylated nonsialylated diantennary species (ɴA2FS0B = 0.56 
± 0.07; pA2FS0B = 4.7·10
-15
). Of particular interest is the high-mannose size trait (MM), which shows 
several of the strongest correlations, positively associating with cholesterol/HDL-C (ɴMM = 0.08 ± 
0.01; pMM < 2.2·10
-16
), TG levels (ɴMM = 0.11 ± 0.01; pMM < 2.2·10-16), leptin (ɴMM = 0.20 ± 0.02; pMM < 
2.2·10
-16
) and BMI (ɴMM = 0.89 ± 0.08; pMM < 2.2·10-16), while negatively associating with 
glucose/insulin (ɴMM = -0.10 ± 0.02; pMM = 3.0·10-10), HDL (ɴMM = -0.09 ± 0.01; pMM < 2.2·10-16), and 
adiponectin (ɴMM = -0.08 ± 0.01; pMM = 1.7·10-15). Considering the individual glycans contributing to 
the MM trait, the significant compositions proved to be H5N2 and H9N2. 
Discussion 
Here we report the MALDI-FTICR-MS analysis of the total plasma N-glycomes of 2,144 principally 
healthy individuals from the LLS, and the association thereof with clinical markers of inflammation 
and metabolic health. In doing so, we have confirmed expectations from literature by showing a 
decrease of galactosylation and increase in bisection of diantennary fucosylated glycans with 
increasing age (59-61), and by men having a higher tri- and tetraantennary fucosylation and lower 
bisection than women (62, 63). Adjusting for the age and sex effects as well as the literature-
reported interaction of age and sex (18, 21), we proved additional associations between clinical 
markers for metabolic health/inflammation and plasma N-glycosylation characteristics including 
antennarity, sialylation, bisection and galactosylation of various diantennary subgroups, and the size 
of high-mannose species. 
Methodology 
MS analysis of plasma N-glycosylation is not without challenges, particularly when employing MALDI 
ionization. A downside of this technique is the in-source and metastable loss of sialic acid residues, 
which is problematic given that plasma N-glycans are often highly sialylated (a notable exception 
being those from the fragment crystallizable (Fc) region of IgG) (16, 37). While chemical 
derivatization prior to MALDI-MS has been found to solve these stabilization issues (e.g. by 
permethylation, methyl/ethyl esterification or amidation), this adds extra steps to the sample 
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preparation workflow and often leads to byproducts (31, 64-69). Instead, here we have used MALDI-
FTICR-MS equipped with an intermediate pressure source to decrease sialic acid decay (36, 38). The 
intermediate pressure source is known to promote ion integrity by cooling of the MALDI-generated 
ions (36, 39-41). In our study this has facilitated the relative quantification of N-glycan species 
containing up to four N-acetylneuraminic acids. 
While similarly sized investigations have analyzed plasma N-glycosylation by separation techniques 
like (U)HPLC or CGE-LIF (18-20, 23, 70), to our knowledge this is the largest study of its kind 
performed by MS (32-34). Glycan compositions as obtained by MS provide orthogonal information to 
chromatographic peaks. UHPLC, for example, can separate diantennary N-glycan isomers with ɲ1,3- 
versus ɲ1,6-arm galactosylation and can likewise distinguish an antennary from a bisecting GlcNAc, 
while MS can provide more precise groups of di-, tri- and tetraantennary compositions, number of 
sialic acids, and clear separation of high-mannose type glycans (29, 71). As such, the construction of 
derived glycosylation traits making use of these features, while still biased on a compositional level, 
is simple to perform and provides additional insight into the complexity of glycan changes.  
One example of the added information of derived traits can be found in the association of 
glycosylation with hsCRP. On an individual glycan level we can only observe a relative increase in tri- 
and tetraantennary compositions together with the inflammation marker, and a corresponding 
relative decrease in all other compositions (which may be due to the total area normalization). 
However, when we mathematically take several individual glycans with shared biological features 
out of the total plasma N-glycome and compare them relative to each other in the form of a derived 
trait, we now additionally reveal, for example, a decrease in galactosylation within the subset of 
glycan compositions predominantly occurring on IgG-Fc (nonsialylated fucosylated diantennary 
species; A2FS0), a finding expected from literature (16, 72, 73). 
Additional aspects of the analytical methodology need to be considered to allow valid interpretation 
of the presented findings. First of all, N-glycans are released from their protein backbones, and thus 
information is lost whether an observed glycan change originates from protein glycosylation or from 
glycoprotein abundance. Secondly, mass spectrometry does not distinguish isomers, meaning that a 
given monosaccharide mass, e.g. a hexose, is assigned differently based on literature knowledge of 
its compositional context (e.g. as mannose for H5N2 and as galactose for H4N4F1) (16, 27, 45, 46). 
Similarly, literature is the main source of information on the linkages between monosaccharides, for 
example presuming bisection for compositions having 5 N-acetylhexosamines but less than three 
galactoses (e.g. H5N5F1). While this group indeed encompasses bisection, the information within will 
also be confounded by triantennary structures with incomplete galactosylation, even if these are not 
15 
 
abundant in human plasma (16, 27). Thirdly, the methodology presented here will not provide 
biologically true relative ratios of glycan compositions, as the profiles will, for example, be skewed by 
the ionization advantage of sialylated species in negative ion mode MS. Nonetheless, the relative 
signal differences will still be representative for the biological directions of change, as well as 
providing an estimate of the magnitude. 
Clinical findings 
With the help of literature, we can speculate on the biological background of the observed 
associations. Acute inflammation, represented in our study by hsCRP and IL-6, shows to confirm 
previous glycomics studies with regard to the increase in antennarity, fucosylation of triantennary 
species, and a decrease in galactosylation of IgG glycans which is particularly well-established (9, 17, 
21, 24, 59, 74). The first two may be explained by an inflammation-induced increase in plasma levels 
and glycosylation changes of acute phase proteins such as alpha-1-antitrypsin and alpha-1-acid 
glycoprotein (orosomucoid-1) (9, 75). Not only are these carriers of N-glycans with two or more 
antennae at baseline conditions, they furthermore display increased antennarity and sialyl-Lewis X 
upon acute inflammation (76-78). Additional observations include the increase of galactosylation and 
sialylation per galactose of diantennary fucosylated (A2F) species in general, which is notably 
different from the behavior of IgG. A contributor to this observation could be the level of IgM, an 
abundant immunoglobulin shown to increase with many autoimmune and inflammatory conditions 
and which carries the required highly galactosylated and sialylated A2F species (79, 80). 
Of particular interest is the highly significantly increased size of high-mannose glycans (MM) which is 
not only observed with increased hsCRP, but as well with increasing BMI, non-HDL cholesterol and 
TG. This glycosylation change appears to largely stem from the increase in the single glycan 
composition H9N2, an analyte difficult to assess by commonly used liquid chromatography with 
fluorescence detection (23, 81). Within the total plasma N-glycome this large high-mannose glycan 
may predominantly originate from apolipoprotein B, the main protein constituent of most non-HDL 
lipoproteins (e.g. VLDL, LDL) (16, 82, 83). The observed correlations with H9N2 and MM can 
represent differing apolipoprotein B levels or glycosylation thereof, and may be indicative of an 
unhealthy glycosylation profile with regard to lipid transport and metabolism. The association of MM 
with inflammatory marker hsCRP is likely a consequence of the connection between inflammation 
and obesity (84), as a model corrected for BMI no longer shows significant association between high 
mannose size and inflammation (data not shown). The effect size being less pronounced with hsCRP 
than with BMI is explainable by the aforementioned increase in IgM, which contains the smaller 
high-mannose compositions H5N2 and H6N2 at its Asn279 site (80). On the other hand, the 
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association between MM and BMI remains true in a model adjusted for CRP and leptin, indicating 
the glycosylation trait may have potential to discriminate healthy from unhealthy obese. 
While largely following an inflammatory glycosylation profile, BMI, leptin, non-HDL cholesterol and 
TG do show a unique negative association with the sialylation of nonfucosylated tetraantennary 
compositions (A4F0GS), a change mainly occurring due to the relative increase of the lowly-sialylated 
H7N6S1 and H7N6S2. Many proteins may contribute to this decrease in sialylation, a notable one 
being alpha-1-acid glycoprotein (85-87), which is known to bind lipophilic compounds with affinity 
modulated by its degree of sialylation (88-90). This effect also applies to binding of hydrophobic 
drugs, possibly explaining why we similarly observed trends of decreased A4F0GS with the usage of 
lipid- and antihypertensive medication (89, 90). Additionally, increased levels of glycoproteins with 
exposed galactose residues can reflect a modulation of protein turnover, e.g. recycling by the liver-
based asialoglycoprotein receptors (5, 91-93). Low sialylation would induce rapid turnover of lipid 
scavengers like alpha-1-acid glycoprotein, a situation which is beneficial when the blood needs to be 
cleared of high levels of lipophilic compounds. 
Smoking proved the only phenotype to positively associate with the fucosylation of tri- and 
tetraantennary species (A3F and A4F), as well as with the bisection of IgG-Fc type glycans (A2FS0B) 
(20, 94). Likely these reflect the chronic response to vascular injury obtained from smoking-induced 
shear stress and oxidative damage (95). Increased fucosylation of acute phase proteins, when 
antennary-linked in the form of sialyl-Lewis X or A, facilitates recruitment to sites of injury, e.g. by 
interactions with selectins presented on inflammation-activated endothelial cells (16, 76, 96).  
While it is invalid to interpret absence of statistical significance as an absence of association, we have 
nevertheless failed to identify derived traits or single glycans to be predictive of DHEA-S, CMV 
infection or the propensity for longevity. The latter is a peculiar absence, as plasma N-glycosylation 
analysis of the same cohort by HPLC had revealed two chromatographic peaks to be predictors of the 
phenotype (18). Reasons for this lack of biological reproduction may include the measurement error 
(HPLC tends to provide more robust measurements than mass spectrometry) (71), the 
chromatographic peaks representing a culmination of multiple mass spectrometric compositions 
which are not individually significant, the previous findings being incidental, or the inability of mass 
spectrometry to separate or detect the responsible analytes. 
Glycosylation is of high interest for the development or improvement of biomarkers for disease and 
patient stratification (14, 97). In particular, the findings within this study may be of benefit to the 
detection and discrimination of metabolic syndrome or inflammatory disorders, and may bolster the 
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predictability of existing biomarkers such as the Framingham Risk Score (98). Important glycosylation 
phenotypes in this regard would then be the derived traits MM, A3F, A4F, A2F0G, A2F0B, A2FS0G, 
A2FGS, and A4F0GS, as well as the various individual glycans comprising these groups, e.g. most tri- 
and tetraantennary compositions, high-mannose compositions H5N2, H6N2 and H9N2, and the 
truncated N-glycans suggested by compositions H3N3, H4N4 and H4N4S1. Interestingly, while this 
last example, H4N4S1, is a glycan composition difficult to characterize in a derived trait, it does show 
to be the major single glycan to positively associate with most beneficial markers of metabolic health 
(e.g. glucose/insulin, HDL-C, adiponectin) and negatively with most detrimental ones (e.g. hsCRP, 
BMI, GGT, hypertension, TG). The protein source of the N-glycan is as of yet unclear, but is of interest 
to study in more detail. 
To summarize, we have reported a large number of associations between total plasma N-
glycosylation as measured by MALDI-FTICR-MS and clinical markers of metabolic health and 
inflammation. By this, we have identified glycan compositions and derived traits indicative of overall 
metabolic health and inflammation, as well as finding glycosylation traits uniquely associating with 
single marker variables. With this knowledge, we hope to contribute to the interpretation of the 
plasma N-glycome as biomarker for health and disease, and to assist clinical translation of mass 
spectrometric glycosylation analysis. 
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Figure Legends 
Figure 1. A typical total plasma N-glycome as analyzed by negative mode MALDI-FTICR-MS after 
enzymatic N-glycan release, 2-AA labeling, and purification. A) Combination of the low mass (red) 
and high mass (blue) mass spectra originating from a single case measurement. The relative 
abundances were normalized to the signal at m/z 2051.733, reflecting the N-glycan composition 
H5N4S1 [M-H]
-
. Whereas the glycan compositions could be established with high confidence, the 
displayed linkages are presumed based on literature knowledge (2, 27, 45, 46). B) Area integration of 
the detectable N-glycan compositions, summing the isotopes within 95% of the isotopic envelope for 
each species. Each composition is represented as a fraction of the total spectrum area. 
Figure 2. Scatterplots with local regression providing an overview of the three main derived 
glycosylation traits changing with age and differing by sex (males in blue, females in red). A) 
Galactosylation of nonsialylated fucosylated diantennary compositions (A2FS0G), to a large degree 
representative of IgG-Fc galactosylation (16). B) Fucosylation of triantennary compositions (A3F). C) 
Bisection of diantennary fucosylated compositions (A2FB). 
Figure 3. Heatmaps showing the t- (or Wald) statistics (ɴ / SE) of the associations between clinical 
markers of metabolic health and inflammation, and glycosylation. A) Single total plasma N-glycans 
after total area normalization. B) Derived glycosylation traits. All models were adjusted for age, sex, 
the interaction thereof, and within-family dependence. Crosses (x) indicate a statistical significance 
of p <= 1.0·10
-5
 thereby surpassing the study-wide significance threshold, whereas periods (.) 
indicate associations with a significance of p <= 0.05. 
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Tables 
Table 1. Non-glycan descriptives for the study population and association thereof with age and sex. 
Displayed are mean values with standard deviation (SD) for continuous variables, and the percentage 
of positive cases for binary variables. To assess if the variables differ by sex (female = 0; male = 1) 
and with age, respective logistic and linear regression was performed. Within-family dependence 
was taken into account by using a sandwich estimator for the standard errors. Effect sizes for the 
traits are displayed as coefficient for the trait  ?ɴ ?ǁŝƚŚstandard error (SE). Displayed in bold are the 
p-values considered significant at or below the study-ǁŝĚĞƐŝŐŶŝĨŝĐĂŶĐĞƚŚƌĞƐŚŽůĚŽĨɲс ? ? ? ? ? ?-5. 
Phenotype 
Total mean 
(SD) or % 
Female 
mean (SD) 
or % 
Male mean 
(SD) or % 
Effect of trait with sex 
(F=0; M=1) 
Effect of trait with age 
n = 2144 n = 1170 n = 974 ɴ ?^ ? p-value ɴ ?^ ? p-value 
Calendar age 59.2 (6.76) 58.6 (6.64) 59.8 (6.84) 0.19 (0.05) 6.1E-05 - - 
Alanine transamidase (IU/L) 24.2 (12.2) 21.8 (11.0) 27.1 (13.0) 0.53 (0.05) <2.2E-16 -0.06 (0.14) 6.9E-01 
Aspartate transamidase (IU/L) 27.0 (7.92) 25.9 (7.71) 28.3 (7.99) 0.36 (0.05) 2.6E-13 0.54 (0.14) 1.8E-04 
AST ALT ratio 1.27 (0.53) 1.33 (0.52) 1.19 (0.54) -0.33 (0.08) 5.7E-05 0.31 (0.15) 3.9E-02 
Gamma-glutamyl transferase (IU/L) 31.4 (37.0) 25.7 (33.2) 38.3 (40.0) 0.74 (0.06) <2.2E-16 0.47 (0.15) 2.2E-03 
Non-fasted glucose (mmol/L) 5.87 (1.58) 5.75 (1.37) 6.01 (1.78) 0.17 (0.05) 2.4E-04 0.58 (0.15) 6.6E-05 
Insulin (mU/L) 23.1 (22.0) 21.0 (17.8) 25.6 (25.9) 0.21 (0.04) 1.3E-06 0.54 (0.14) 1.8E-04 
Glucose insulin ratio 0.46 (0.39) 0.49 (0.41) 0.43 (0.37) -0.18 (0.04) 3.8E-05 -0.38 (0.14) 8.0E-03 
Total cholesterol (mmol/L) 5.59 (1.17) 5.68 (1.21) 5.47 (1.12) -0.19 (0.05) 3.4E-05 0.02 (0.16) 8.9E-01 
Low-density lipoprotein cholesterol 
(mmol/L) 
3.34 (0.96) 3.37 (0.98) 3.30 (0.94) -0.07 (0.04) 1.1E-01 -0.10 (0.15) 5.0E-01 
High-density lipoprotein cholesterol 
(mmol/L) 
1.44 (0.46) 1.59 (0.47) 1.26 (0.36) -0.89 (0.06) <2.2E-16 -0.38 (0.15) 9.1E-03 
Total cholesterol HDL ratio 4.20 (1.41) 3.82 (1.22) 4.65 (1.49) 0.69 (0.05) <2.2E-16 0.40 (0.15) 7.0E-03 
Triglycerides (mmol/L) 1.82 (1.16) 1.60 (0.93) 2.07 (1.34) 0.48 (0.05) <2.2E-16 0.74 (0.15) 5.3E-07 
Lipid lowering medication (%) 10.8% 8.87% 13.1% 0.14 (0.04) 1.6E-03 1.13 (0.12) <2.2E-16 
Leptin (ng/mL) 20.5 (21.6) 29.3 (24.7) 9.92 (9.83) -1.61 (0.09) <2.2E-16 0.17 (0.15) 2.6E-01 
Adiponectin (mg/L) 6.27 (3.30) 7.49 (3.55) 4.81 (2.23) -1.04 (0.06) <2.2E-16 0.08 (0.15) 5.7E-01 
Body mass index 25.4 (3.58) 25.1 (4.00) 25.7 (2.97) 0.18 (0.05) 7.1E-04 0.41 (0.15) 4.4E-03 
Hypertension (%) 24.2% 24.3% 24.0% -0.01 (0.05) 8.8E-01 1.12 (0.15) 5.0E-14 
Antihypertensive medication (%) 20.5% 20.3% 20.7% 0.01 (0.05) 7.5E-01 1.38 (0.15) <2.2E-16 
Dehydroepiandrosterone sulfate 
(ʅŵŽů ?>) 4.45 (2.80) 3.59 (2.21) 5.49 (3.07) 0.85 (0.06) <2.2E-16 -1.87 (0.16) <2.2E-16 
High sensitivity C-reactive protein 
(mg/L) 
3.15 (11.0) 3.11 (10.4) 3.21 (11.7) -0.05 (0.04) 2.9E-01 0.63 (0.15) 3.5E-05 
Interleukin 6 (pg/mL) 0.68 (1.46) 0.62 (1.17) 0.75 (1.74) 0.11 (0.04) 9.8E-03 0.77 (0.15) 5.6E-07 
Smoking (%) 13.6% 13.2% 14.1% 0.02 (0.05) 6.1E-01 -0.90 (0.15) 2.4E-09 
Free triiodothyronine (pmol/L) 4.11 (0.72) 3.94 (0.71) 4.31 (0.67) 0.62 (0.07) <2.2E-16 -0.55 (0.14) 9.4E-05 
Cytomegalovirus infection (%) 46.9% 50.6% 42.3% -0.17 (0.05) 5.3E-04 0.56 (0.16) 4.9E-04 
Member of long-lived family (%) 69.2% 67.4% 71.4% 0.09 (0.04) 5.3E-02 0.33 (0.17) 5.0E-02 
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Table 2. N-glycan descriptives and their association with age and sex. Displayed are mean values with 
SD. To assess if the variables differ by sex (female = 0; male = 1) and with age, respective logistic and 
linear regression was performed, adjusted for within-family dependence.. Effect sizes for the traits 
are displayed as coefficient for the trait  ?ɴ ?ǁŝƚŚ^, all of which are representative of a 1 SD increase 
in the glycosylation value. Displayed in bold are the p-values considered significant at or below the 
study-ǁŝĚĞƐŝŐŶŝĨŝĐĂŶĐĞƚŚƌĞƐŚŽůĚŽĨɲс ? ? ? ? ?0-5. 
Composition 
m/z [M-
H]- 
Depiction 
Total 
mean % 
(SD) 
Female 
mean % 
(SD) 
Male 
mean % 
(SD) 
Effect of trait with sex 
(F=0; M=1) 
Effect of trait with age 
ɴ ?^ ? p-value ɴ ?^ ? p-value 
H4N2 1192.43 
 
0.05 (0.01) 0.05 (0.01) 0.05 (0.01) -0.04 (0.04) 2.9E-01 -0.19 (0.13) 1.6E-01 
H3N3 1233.45 
 
0.00 (0.00) 0.00 (0.00) 0.00 (0.00) 0.09 (0.05) 4.1E-02 -0.45 (0.15) 3.5E-03 
H5N2 1354.48 
 
0.14 (0.04) 0.14 (0.04) 0.13 (0.04) -0.10 (0.04) 2.4E-02 -0.22 (0.14) 1.2E-01 
H3N3F1 1379.51 
 
0.06 (0.02) 0.06 (0.02) 0.06 (0.02) 0.15 (0.04) 2.2E-04 0.20 (0.15) 1.8E-01 
H4N3 1395.51 
 
0.11 (0.03) 0.11 (0.03) 0.11 (0.03) -0.02 (0.04) 5.5E-01 -0.13 (0.13) 3.1E-01 
H3N4 1436.53 
 
0.06 (0.03) 0.06 (0.03) 0.06 (0.03) 0.11 (0.05) 1.7E-02 1.21 (0.14) <2.2E-16 
H6N2 1516.53 
 
0.20 (0.06) 0.20 (0.06) 0.20 (0.06) -0.06 (0.04) 1.5E-01 -0.54 (0.14) 2.1E-04 
H3N3S1 1524.55 
 
0.34 (0.07) 0.34 (0.07) 0.34 (0.07) 0.03 (0.04) 4.6E-01 -0.23 (0.14) 9.0E-02 
H4N3F1 1541.56 
 
0.06 (0.02) 0.06 (0.02) 0.06 (0.02) 0.13 (0.04) 1.8E-03 -0.97 (0.15) 1.1E-10 
H5N3 1557.56 
 
0.04 (0.01) 0.04 (0.01) 0.03 (0.01) -0.16 (0.05) 4.5E-04 -0.44 (0.14) 2.6E-03 
H3N4F1 1582.59 
 
1.18 (0.49) 1.15 (0.49) 1.23 (0.48) 0.18 (0.04) 3.1E-05 1.50 (0.14) <2.2E-16 
H4N4 1598.58 
 
0.19 (0.06) 0.19 (0.06) 0.19 (0.06) 0.00 (0.04) 9.5E-01 -0.10 (0.15) 5.0E-01 
H3N5 1639.61 
 
0.06 (0.02) 0.06 (0.02) 0.06 (0.02) 0.10 (0.04) 2.9E-02 1.68 (0.14) <2.2E-16 
H3N3F1S1 1670.61 
 
0.05 (0.01) 0.05 (0.01) 0.06 (0.01) 0.21 (0.04) 8.3E-07 -0.30 (0.15) 4.4E-02 
H7N2 1678.58 
 
0.08 (0.02) 0.08 (0.02) 0.07 (0.02) -0.03 (0.04) 5.5E-01 -0.58 (0.15) 8.0E-05 
H4N3S1 1686.60 
 
0.61 (0.12) 0.60 (0.12) 0.61 (0.12) 0.08 (0.04) 4.8E-02 -0.12 (0.14) 4.0E-01 
H5N3F1 1703.62 
 
0.01 (0.01) 0.01 (0.01) 0.01 (0.01) -0.08 (0.04) 8.3E-02 -0.53 (0.14) 1.9E-04 
H6N3 1719.61 
 
0.05 (0.01) 0.05 (0.01) 0.05 (0.01) 0.06 (0.04) 1.7E-01 0.72 (0.15) 1.7E-06 
H3N4S1 1727.63 
 
0.05 (0.01) 0.05 (0.01) 0.05 (0.01) -0.03 (0.04) 4.6E-01 -0.26 (0.14) 5.6E-02 
H4N4F1 1744.64 
 
1.40 (0.46) 1.36 (0.45) 1.44 (0.47) 0.19 (0.04) 9.1E-06 -0.33 (0.15) 3.1E-02 
H5N4 1760.64 
 
0.90 (0.18) 0.90 (0.18) 0.89 (0.18) -0.06 (0.05) 1.6E-01 -0.32 (0.14) 2.4E-02 
H3N5F1 1785.67 
 
0.30 (0.11) 0.29 (0.11) 0.30 (0.11) 0.09 (0.04) 4.8E-02 1.67 (0.14) <2.2E-16 
H4N5 1801.66 
 
0.07 (0.02) 0.06 (0.02) 0.07 (0.02) 0.05 (0.05) 2.7E-01 0.83 (0.15) 1.6E-08 
H4N3F1S1 1832.66 
 
0.10 (0.02) 0.10 (0.02) 0.10 (0.02) 0.15 (0.04) 5.0E-04 -0.46 (0.15) 2.3E-03 
H8N2 1840.64 
 
0.12 (0.03) 0.12 (0.03) 0.12 (0.03) -0.12 (0.04) 4.2E-03 -0.73 (0.14) 4.5E-07 
H5N3S1 1848.65 
 
0.10 (0.02) 0.11 (0.02) 0.10 (0.02) -0.20 (0.05) 1.6E-05 0.73 (0.15) 1.1E-06 
H3N4F1S1 1873.69 
 
0.03 (0.01) 0.03 (0.01) 0.03 (0.01) -0.02 (0.04) 7.3E-01 0.13 (0.14) 3.7E-01 
H4N4S1 1889.68 
 
0.37 (0.08) 0.37 (0.09) 0.36 (0.08) -0.19 (0.04) 9.0E-06 0.25 (0.14) 6.9E-02 
H5N4F1 1906.70 
 
0.62 (0.19) 0.61 (0.20) 0.63 (0.19) 0.14 (0.04) 1.4E-03 -1.60 (0.15) <2.2E-16 
H4N5F1 1947.72 
 
0.29 (0.09) 0.28 (0.09) 0.29 (0.10) 0.06 (0.04) 1.6E-01 0.09 (0.15) 5.5E-01 
H5N5 1963.72 
 
0.03 (0.01) 0.03 (0.01) 0.03 (0.01) -0.12 (0.04) 8.7E-03 -0.43 (0.15) 5.3E-03 
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Composition 
m/z [M-
H]- 
Depiction 
Total 
mean % 
(SD) 
Female 
mean % 
(SD) 
Male 
mean % 
(SD) 
Effect of trait with sex 
(F=0; M=1) 
Effect of trait with 
age 
ɴ ?^ ? p-value ɴ ?^ ? p-value 
H5N3F1S1 1994.71 
 
0.01 (0.01) 0.01 (0.01) 0.01 (0.01) 0.00 (0.04) 9.9E-01 -0.33 (0.15) 2.6E-02 
H9N2 2002.69 
 
0.20 (0.04) 0.20 (0.04) 0.20 (0.04) 0.12 (0.04) 6.2E-03 -0.21 (0.14) 1.4E-01 
H6N3S1 2010.71 
 
0.09 (0.02) 0.09 (0.02) 0.09 (0.02) -0.16 (0.04) 4.9E-04 0.29 (0.14) 4.5E-02 
H4N4F1S1 2035.74 
 
0.23 (0.05) 0.23 (0.05) 0.24 (0.05) 0.20 (0.04) 2.6E-06 -0.31 (0.15) 3.6E-02 
H8N3 2043.72 
 
0.01 (0.01) 0.01 (0.01) 0.01 (0.01) 0.02 (0.04) 6.4E-01 -0.84 (0.14) 5.0E-09 
H5N4S1 2051.73 
 
6.94 (0.88) 6.97 (0.89) 6.91 (0.87) -0.06 (0.04) 1.5E-01 0.01 (0.14) 9.4E-01 
H5N5F1 2109.77 
 
0.15 (0.05) 0.15 (0.05) 0.15 (0.05) -0.04 (0.04) 3.4E-01 -0.62 (0.15) 4.7E-05 
H5N4F1S1 2197.79 
 
2.14 (0.46) 2.08 (0.45) 2.20 (0.46) 0.27 (0.05) 5.1E-09 -0.81 (0.15) 4.5E-08 
H4N5F1S1 2238.82 
 
0.10 (0.04) 0.10 (0.04) 0.10 (0.04) -0.01 (0.04) 7.2E-01 0.95 (0.14) 3.4E-12 
H5N5S1 2254.81 
 
0.16 (0.05) 0.16 (0.05) 0.16 (0.05) -0.03 (0.04) 5.1E-01 -0.20 (0.15) 1.7E-01 
H5N4S2 2342.83 
 
24.03 (2.94) 23.9 (2.93) 24.2 (2.94) 0.09 (0.04) 2.5E-02 -0.33 (0.14) 1.7E-02 
H6N4F1S1 2359.84 
 
0.13 (0.04) 0.13 (0.04) 0.13 (0.05) 0.04 (0.04) 3.2E-01 -0.29 (0.15) 5.3E-02 
H5N5F1S1 2400.87 
 
1.74 (0.55) 1.77 (0.57) 1.72 (0.52) -0.10 (0.04) 1.6E-02 -0.26 (0.15) 9.2E-02 
H6N5S1 2416.87 
 
1.55 (0.30) 1.64 (0.30) 1.45 (0.28) -0.71 (0.05) <2.2E-16 -0.51 (0.14) 3.4E-04 
H5N4F1S2 2488.89 
 
4.38 (0.92) 4.20 (0.84) 4.59 (0.95) 0.45 (0.05) <2.2E-16 0.05 (0.14) 7.2E-01 
H5N5S2 2545.91 
 
0.26 (0.06) 0.27 (0.06) 0.25 (0.06) -0.18 (0.04) 3.2E-05 -0.54 (0.14) 1.6E-04 
H6N5F1S1 2562.92 
 
0.93 (0.23) 0.88 (0.21) 0.99 (0.23) 0.53 (0.05) <2.2E-16 0.71 (0.15) 1.1E-06 
H5N5F1S2 2691.97 
 
2.89 (0.87) 2.84 (0.85) 2.96 (0.88) 0.14 (0.04) 1.9E-03 0.24 (0.15) 1.1E-01 
H6N5S2 2707.96 
 
7.65 (1.54) 8.08 (1.49) 7.13 (1.43) -0.70 (0.05) <2.2E-16 -0.59 (0.15) 6.6E-05 
H7N6S1 2782.00 
 
0.50 (0.16) 0.54 (0.16) 0.46 (0.14) -0.58 (0.05) <2.2E-16 0.07 (0.13) 6.1E-01 
H6N5F1S2 2854.02 
 
4.02 (1.20) 3.73 (1.09) 4.38 (1.22) 0.58 (0.05) <2.2E-16 0.77 (0.15) 2.2E-07 
H7N6F1S1 2928.06 
 
0.28 (0.10) 0.27 (0.10) 0.30 (0.10) 0.38 (0.05) <2.2E-16 0.87 (0.14) 1.8E-09 
H6N5S3 2999.06 
 
14.99 (3.25) 15.8 (3.17) 14.0 (3.07) -0.61 (0.05) <2.2E-16 -0.67 (0.16) 1.6E-05 
H7N6S2 3073.09 
 
1.74 (0.47) 1.85 (0.48) 1.62 (0.43) -0.53 (0.05) <2.2E-16 0.05 (0.14) 7.2E-01 
H6N5F1S3 3145.11 
 
7.81 (2.53) 7.15 (2.31) 8.59 (2.57) 0.61 (0.05) <2.2E-16 0.74 (0.15) 8.1E-07 
H7N6F1S2 3219.15 
 
1.08 (0.35) 1.01 (0.33) 1.17 (0.35) 0.48 (0.05) <2.2E-16 0.90 (0.14) 2.4E-10 
H7N6S3 3364.19 
 
2.35 (0.62) 2.48 (0.62) 2.20 (0.57) -0.50 (0.05) <2.2E-16 -0.07 (0.15) 6.3E-01 
H7N6F1S3 3510.25 
 
1.20 (0.36) 1.12 (0.34) 1.28 (0.36) 0.46 (0.05) <2.2E-16 0.88 (0.15) 1.2E-09 
H7N6S4 3655.28 
 
1.96 (0.47) 2.01 (0.48) 1.89 (0.46) -0.26 (0.05) 5.8E-08 0.16 (0.15) 2.8E-01 
H7N6F1S4 3801.34 
 
1.05 (0.30) 0.99 (0.28) 1.12 (0.31) 0.45 (0.05) <2.2E-16 0.79 (0.14) 1.8E-08 
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Table 3. Derived glycosylation trait descriptives and their association with age and sex. Displayed are 
mean values with SD. To assess if the variables differ by sex (female = 0; male = 1) and with age, 
respective logistic and linear regression was performed, adjusted for within-family dependence. 
Effect sizes for the traits are displayed as coefficient for the trait  ?ɴ) with SE, and are representative 
of a 1 SD increase in the glycosylation value. Displayed in bold are the p-values considered significant 
at or below the study-ǁŝĚĞƐŝŐŶŝĨŝĐĂŶĐĞƚŚƌĞƐŚŽůĚŽĨɲс ? ? ? ? ? ?-5. 
Derived 
trait 
Description 
Total 
mean % 
(SD) 
Female 
mean % 
(SD) 
Male 
mean % 
(SD) 
Effect of trait with sex 
(F=0; M=1) 
Effect of trait with age 
ɴ ?^ ? p-value ɴ ?^ ? p-value 
Complexity 
M Overall high mannose type 0.78 (0.17) 0.78 (0.17) 0.78 (0.17) -0.03 (0.04) 4.5E-01 -0.51 (0.14) 3.9E-04 
MM High mannose occupancy 690 (11.0) 689 (11.0) 691 (11.0) 0.19 (0.04) 2.1E-05 -0.12 (0.14) 4.0E-01 
Hy Overall hybrid type 0.44 (0.09) 0.45 (0.09) 0.44 (0.09) -0.07 (0.04) 1.0E-01 0.06 (0.14) 6.6E-01 
C Overall complex type 97.3 (0.46) 97.3 (0.47) 97.3 (0.45) -0.02 (0.04) 7.0E-01 0.36 (0.14) 1.0E-02 
A1 Overall monoantennary 1.16 (0.22) 1.15 (0.23) 1.17 (0.22) 0.10 (0.04) 1.6E-02 -0.21 (0.14) 1.3E-01 
A2 Overall diantennary 49.2 (5.32) 48.8 (5.30) 49.7 (5.30) 0.18 (0.04) 3.5E-05 -0.09 (0.15) 5.5E-01 
A3 Overall triantennary 37.1 (4.50) 37.5 (4.46) 36.7 (4.51) -0.18 (0.04) 2.2E-05 -0.10 (0.15) 5.0E-01 
A4 Overall tetraantennary 10.2 (1.95) 10.3 (2.01) 10.1 (1.86) -0.13 (0.04) 3.4E-03 0.52 (0.14) 2.6E-04 
Fucosylation 
F Overall 33.0 (5.58) 31.4 (5.21) 35.0 (5.37) 0.72 (0.05) <2.2E-16 0.78 (0.15) 3.9E-07 
A2F Within A2 32.4 (4.47) 31.9 (4.48) 32.9 (4.41) 0.22 (0.04) 3.3E-07 0.19 (0.15) 1.9E-01 
A3F Within A3 34.7 (9.87) 31.7 (9.04) 38.2 (9.67) 0.73 (0.05) <2.2E-16 0.82 (0.15) 7.4E-08 
A4F Within A4 35.6 (8.41) 33.1 (7.85) 38.7 (8.05) 0.74 (0.05) <2.2E-16 0.77 (0.15) 2.0E-07 
Bisection 
B Overall 6.12 (1.52) 6.09 (1.54) 6.17 (1.51) 0.05 (0.04) 2.2E-01 0.18 (0.15) 2.2E-01 
A2B Within A2 12.5 (2.79) 12.5 (2.86) 12.4 (2.71) -0.05 (0.04) 2.1E-01 0.28 (0.15) 5.8E-02 
A2F0B Within nonfucosylated A2 1.77 (0.41) 1.78 (0.41) 1.75 (0.41) -0.09 (0.04) 3.7E-02 0.16 (0.15) 3.1E-01 
A2FB Within fucosylated A2 34.7 (4.87) 35.3 (4.84) 34.0 (4.81) -0.27 (0.04) 3.8E-10 0.24 (0.14) 8.7E-02 
A2FS0B Within nonsialylated fucosylated A2 18.9 (2.99) 19.2 (2.94) 18.5 (3.01) -0.25 (0.04) 1.1E-08 0.77 (0.14) 6.7E-08 
A2FSB Within sialylated fucosylated A2 40.9 (5.91) 41.6 (5.88) 40.1 (5.85) -0.25 (0.04) 4.5E-09 0.24 (0.15) 9.4E-02 
Galactosylation per antenna 
AG Overall 96.5 (1.11) 96.6 (1.10) 96.4 (1.11) -0.15 (0.04) 3.9E-04 -0.94 (0.15) 1.3E-10 
A2G Within A2 93.3 (1.68) 93.4 (1.71) 93.2 (1.65) -0.10 (0.04) 1.5E-02 -1.25 (0.14) <2.2E-16 
A2F0G Within nonfucosylated A2 98.5 (0.30) 98.5 (0.30) 98.5 (0.29) 0.05 (0.04) 2.6E-01 -0.99 (0.14) 5.4E-13 
A2F0S0G Within nonsialylated nonfucosylated A2 81.1 (3.84) 81.3 (3.94) 80.8 (3.69) -0.14 (0.05) 2.4E-03 -1.32 (0.15) <2.2E-16 
A2FG Within fucosylated A2 82.6 (3.97) 82.6 (4.04) 82.6 (3.89) -0.03 (0.04) 4.8E-01 -1.36 (0.14) <2.2E-16 
A2FS0G Within nonsialylated fucosylated A2 41.4 (5.40) 41.7 (5.80) 41.2 (4.86) -0.10 (0.04) 2.1E-02 -2.82 (0.13) <2.2E-16 
A2FSG Within sialylated fucosylated A2 98.5 (0.26) 98.5 (0.26) 98.5 (0.26) 0.10 (0.04) 1.7E-02 -0.50 (0.14) 3.5E-04 
Sialylation per antenna 
AS Overall 79.1 (1.71) 79.1 (1.69) 79.1 (1.72) 0.02 (0.04) 5.5E-01 -0.41 (0.15) 5.2E-03 
A2S Within A2 76.6 (2.47) 76.6 (2.45) 76.6 (2.50) 0.00 (0.04) 9.8E-01 -0.35 (0.15) 1.6E-02 
A2F0S Within nonfucosylated A2 84.5 (1.31) 84.4 (1.30) 84.6 (1.32) 0.18 (0.04) 1.0E-05 -0.56 (0.13) 3.4E-05 
A2FS Within fucosylated A2 60.1 (4.79) 60.0 (4.71) 60.3 (4.89) 0.05 (0.04) 2.3E-01 -0.20 (0.15) 1.7E-01 
Sialylation per galactose 
GS Overall 81.9 (1.18) 81.8 (1.18) 82.0 (1.17) 0.17 (0.04) 6.0E-05 0.23 (0.15) 1.2E-01 
A2GS Within A2 82.1 (1.53) 82.0 (1.53) 82.2 (1.52) 0.11 (0.04) 7.4E-03 0.63 (0.15) 2.4E-05 
A2F0GS Within nonfucosylated A2 85.8 (1.17) 85.7 (1.16) 85.8 (1.18) 0.19 (0.04) 1.2E-05 -0.34 (0.14) 1.4E-02 
A2FGS Within fucosylated A2 72.7 (3.37) 72.5 (3.38) 73.0 (3.33) 0.14 (0.04) 1.2E-03 1.14 (0.15) 9.8E-15 
A3GS Within A3 84.8 (1.01) 84.7 (0.98) 84.8 (1.05) 0.12 (0.04) 3.5E-03 -0.15 (0.14) 2.8E-01 
A3F0GS Within nonfucosylated A3 84.9 (1.09) 84.9 (1.05) 84.9 (1.14) 0.01 (0.04) 7.8E-01 -0.30 (0.14) 3.7E-02 
A3FGS Within fucosylated A3 84.2 (1.32) 84.0 (1.32) 84.5 (1.28) 0.34 (0.04) 2.7E-14 0.22 (0.14) 1.2E-01 
A4GS Within A4 71.4 (1.93) 71.3 (1.88) 71.6 (1.96) 0.16 (0.04) 9.0E-05 -0.11 (0.14) 4.3E-01 
A4F0GS Within nonfucosylated A4 71.9 (2.16) 71.6 (2.05) 72.3 (2.22) 0.34 (0.04) 2.5E-14 0.09 (0.14) 5.1E-01 
A4FGS Within fucosylated A4 70.8 (1.96) 70.8 (1.95) 70.7 (1.97) -0.08 (0.04) 5.2E-02 -0.24 (0.14) 8.7E-02 
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